Clinical Trial Update: A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for F520 in relapsed/refractory PCNSL and SCNSL.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• F520

Snippet

Sponsor: Shandong New Time Pharmaceutical Co., LTD | Conditions: Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Status: UNKNOWN